Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number.

× No keyword cloud information.

7 in total

1. Whole-exome sequencing identifies key mutated genes in T790M wildtype/cMET-unamplified lung adenocarcinoma with acquired resistance to first-generation EGFR tyrosine kinase inhibitors.

Authors: Chenguang Li; Hailin Liu; Bin Zhang; Liqun Gong; Yanjun Su; Zhenfa Zhang; Changli Wang
Journal: J Cancer Res Clin Oncol Date: 2018-04-03 Impact factor: 4.553

2. EGFR L861Q Mutation in a Metastatic Solid-pseudopapillary Neoplasm of the Pancreas.

Authors: Kevin G Neill; James Saller; Sameer Al Diffalha; Barbara A Centeno; Mokenge P Malafa; Domenico Coppola
Journal: Cancer Genomics Proteomics Date: 2018 May-Jun Impact factor: 4.069

Review 3. Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 cases.

Authors: Giuseppe Lo Russo; Martina Imbimbo; Giulia Corrao; Claudia Proto; Diego Signorelli; Milena Vitali; Monica Ganzinelli; Laura Botta; Nicoletta Zilembo; Filippo de Braud; Marina Chiara Garassino
Journal: Oncotarget Date: 2017-04-26

4. SPP1 overexpression is associated with poor outcomes in ALK fusion lung cancer patients without receiving targeted therapy.

Authors: Xiaolin Ji; Yan Liu; Fang Mei; Xinyang Li; Mengxue Zhang; Buwen Yao; Rui Wu; Jiangfeng You; Fei Pei
Journal: Sci Rep Date: 2021-07-07 Impact factor: 4.379

Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number.

1. Whole-exome sequencing identifies key mutated genes in T790M wildtype/cMET-unamplified lung adenocarcinoma with acquired resistance to first-generation EGFR tyrosine kinase inhibitors.

2. EGFR L861Q Mutation in a Metastatic Solid-pseudopapillary Neoplasm of the Pancreas.

Review 3. Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 cases.

4. SPP1 overexpression is associated with poor outcomes in ALK fusion lung cancer patients without receiving targeted therapy.

5. Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer.

6. Increased levels of the long noncoding RNA, HOXA-AS3, promote proliferation of A549 cells.

7. [Analyzing the Sensitivity of EGFR-L861Q Mutation to TKIs and A Case Report].